|Mr. Jed A. Latkin||CEO, COO, CFO & Director||639.88k||N/A||1974|
|Dr. Michael Stanley Rosol Ph.D.||Chief Medical Officer||222.6k||N/A||1968|
|Erika Gibson||Director of Fin. & Admin.||N/A||N/A||N/A|
|Mr. William J. Regan||Chief Compliance Officer||N/A||N/A||1952|
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. In addition, the company offers NAV4694, a fluorine-18 labeled PET imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. Further, the company is developing diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. Navidea Biopharmaceuticals, Inc. has a preclinical therapeutic research collaboration with IMV Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Navidea Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 6; Compensation: 8.